title: [Treatment of a large intracoronary thrombus with urokinase and a chimeric monoclonal platelet aggregation inhibitor].
abstract: METHODS
  7 days after an operation for intervertebral disc prolapse a 43-year-old man was referred with the clinical and ECG signs of an acute posterior wall myocardial infarction.
  
  
  METHODS
  Creatine kinase (CK) activity was raised to 204 U/I (myocardial-specific isoenzyme CKMB of 23.6 U/I, 11.6% of total) and glutamic-oxalate transferase (GOT) activity to 37 U/I. Emergency cardiac catheterisation, performed 4 hours after renewed onset of precordial pain showed no abnormal findings in the right coronary artery, despite the ECG signs, but a definite filling defect in the anterior interventricular branch, which on intravascular ultrasound was an echo-dense noncalcified structure.
  
  
  METHODS
  After percutaneous transluminal coronary angioplasty in the area of the obstructing structure a free-floating mass was identified in the proximal part of the anterior interventricular branch, most likely a thrombus. Intercoronary thrombolysis was therefore undertaken with urokinase (bolus of 1 mill. IU) together with the chimeric monoclonal antibody c7E3, which inhibits platelet aggregation by blocking the platelet glycoprotein surface receptor IIb/IIIa. Coronary angiography 12 hours later revealed almost complete dissolution of the previously obstructing mass.
  
  
  CONCLUSIONS
  Combining the platelet aggregation inhibitor c7E3 with a thrombolytic agent is an alternative treatment to the current management of intracoronary thrombi. Intravascular ultrasound is a suitable method for demonstrating angiographically inconspicuous or unclear but pathogenetically significant vessel changes.
authors.affiliation: Abteilung für Kardiologie, Universität Essen.
authors.forename: B
authors.initials: B
authors.lastname: Eick
authors.forename: M
authors.initials: M
authors.lastname: Haude
authors.forename: C
authors.initials: C
authors.lastname: Altmann
authors.forename: F
authors.initials: F
authors.lastname: Liu
authors.forename: G
authors.initials: G
authors.lastname: Caspari
authors.forename: R
authors.initials: R
authors.lastname: Leischik
authors.forename: R
authors.initials: R
authors.lastname: Erbel
mesh_terms: D000077284:Abciximab; D000328:Adult; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000188:drug therapy*; D003937:Diagnosis, Differential; D004562:Electrocardiography; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007405:Intervertebral Disc Displacement / Q000601:surgery; D008159:Lumbar Vertebrae; D008297:Male; D010960:Plasminogen Activators / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000628:therapy; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D000077284:Abciximab